Astrazeneca plc - ADR
AZN
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 29, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
122% upsideUndervalued by 122% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $294.40 Billion |
|---|---|
| Enterprise Value | $319.39 Billion |
| Dividend Yield | $3.20 (1.71%) |
| Earnings per Share | $6.6 |
| Beta | 0.22 |
| Outstanding Shares | 1,549,000,000 |
Return
| Return on Equity | 21.16% |
|---|---|
| Return on Assets | 9.03% |
| Return on Invested Capital | 16.80% |
Valuation & Multiples
| P/E Ratio | 27.52 |
|---|---|
| PEG | 49.97 |
| Price to Sales | 4.76 |
| Price to Book Ratio | 5.69 |
| Enterprise Value to Revenue | 5.44 |
| Enterprise Value to EBIT | 22.78 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9628▲ 27.02% |
|---|---|
| Total Calls | 3,479,401▼ 35.47% |
| Total Puts | 3,350,045▼ 10.29% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 96.56%▲ 64.96% |
|---|---|
| Total Invested | $149.90B▲ 232.68% |
| Investors Holding | 1,354▼ 45.00% |
ESG Score
No data
About AstraZeneca Plc
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...
Relevant Senate Committees
This is a critically important committee for AstraZeneca. It controls taxation (corporate tax rates, R&D credits), trade policy (affecting global supply chains and market access), and entitlement spending (Medicare/Medicaid drug pricing and reimbursement), all directly impacting profitability and revenue.
This committee allocates federal discretionary spending, directly impacting funding for biomedical research (e.g., NIH) and government healthcare programs that purchase pharmaceutical products, thereby affecting AstraZeneca's potential research collaborations and market opportunities.
This committee directly regulates the FDA (drug approval, safety, marketing) and NIH (research funding), making it central to AstraZeneca's product development, regulatory pathways, and market access. It profoundly impacts the pharmaceutical and biotech sectors.
This committee's oversight of antitrust laws directly impacts potential mergers and acquisitions, and its role in intellectual property protection (patents) is critical for pharmaceutical companies like AstraZeneca, which rely heavily on proprietary research and development.